文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Obicetrapib 治疗杂合子家族性高胆固醇血症患者:BROOKLYN 随机临床试验

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial.
PubMed 文献 · Nat Med · 2026-02-27

BROOKLYN 随机试验纳入 354 例已接受最大耐受降脂治疗且 LDL 胆固醇≥70 mg/dl 的杂合子家族性高胆固醇血症患者,按 2:1 随机接受 obicetrapib 10 mg 或安慰剂每日一次治疗 365 天。第 84 天 obicetrapib 组 LDL 胆固醇安慰剂校正变化为 -36.3%(95%CI -42.2% 至 -30.4%,P<0.0001),药物耐受良好。

要点

  • obicetrapib 10 mg 每日一次使杂合子家族性高胆固醇血症患者第 84 天 LDL 胆固醇安慰剂校正降低 36.3%。
  • 第 84 天载脂蛋白 B 安慰剂校正降低 24.4%,非 HDL 胆固醇降低 34.5%,脂蛋白(a)降低 45.9%。
  • 第 84 天高密度脂蛋白胆固醇安慰剂校正升高 138.7%,obicetrapib 耐受良好。

核心结论

  • 这些发现提示 obicetrapib 是杂合子家族性高胆固醇血症患者进一步降低血脂的有效治疗。

研究设计与样本

  • 随机试验纳入 354 例(女 190 例、男 164 例)接受最大耐受降脂治疗且 LDL 胆固醇≥70 mg/dl 的杂合子家族性高胆固醇血症患者,平均 LDL 胆固醇 122 mg/dl,87% 使用他汀。
  • 患者按 2:1 随机接受 obicetrapib 10 mg 或安慰剂每日一次治疗 365 天。
  • 主要终点为基线至第 84 天 LDL 胆固醇变化。

主要发现

  • 主要终点:第 84 天 LDL 胆固醇安慰剂校正变化为 -36.3%(95%CI -42.2% 至 -30.4%,P<0.0001)。
  • 第 84 天次要终点:载脂蛋白 B 安慰剂校正降低 24.4%,非 HDL 胆固醇降低 34.5%,脂蛋白(a)降低 45.9%。
  • 第 84 天高密度脂蛋白胆固醇安慰剂校正升高 138.7%。
  • obicetrapib 耐受良好。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with heterozygous familial hypercholesterolemia fail to achieve adequate low-density lipoprotein (LDL) cholesterol lowering. Here we carried out a randomized trial to test the safety and efficacy of obicetrapib, a highly selective cholesteryl ester transfer protein inhibitor that lowers LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia and an LDL cholesterol level ≥70 mg dl-1 on maximally tolerated lipid-lowering therapy. The trial enrolled 354 patients (190 women, 164 men) with a mean LDL cholesterol level of 122 mg dl-1 (87% on statins) who were randomized (2:1) to receive obicetrapib 10 mg or placebo daily for 365 days. For the primary endpoint, the change in LDL cholesterol from baseline to day 84, obicetrapib treatment resulted in a placebo-adjusted change in LDL cholesterol of -36.3% (95% confidence interval -42.2% to -30.4%, P < 0.0001). In analyses of secondary endpoints at day 84, treatment with obicetrapib resulted in placebo-adjusted reductions in apolipoprotein B of -24.4%, non-HDL cholesterol of -34.5% and lipoprotein(a) of -45.9%, as well as a placebo-adjusted increase in high-density lipoprotein cholesterol of +138.7%. Obicetrapib was well tolerated. These findings suggest that obicetrapib is an effective therapy for additional lipid lowering in patients with heterozygous familial hypercholesterolemia. ClinicalTrials.gov registration: NCT05425745 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026. PMID: 41760952. doi:10.1038/s41591-025-04179-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。